Bispecific T cell-redirecting antibodies are typically designed to bind to the CD3 chain, the signaling-invariant component of the TCR complex, and to a selected Tumor-Associated Antigen (TAA) [93]; in the context of AML, they are mainly directed against CD123 [94], CD33 [15], and CLL1 [95] (Table 3). Here, CD33 is linked to acute myeloid leukemia.